We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Department of Homeland Security as agreed to end U.S. Customs and Border Protection's role in confiscating prescription drugs mailed to American consumers from Canadian pharmacies, Sen. Bill Nelson (D-Fla.) has announced.
Researchers at Karolinska Institutet in Stockholm, Sweden, have developed a powerful new treatment for most dangerous form of malaria, which is difficult to treat and claims 2 million lives a year.
A.P. Pharma and RHEI Pharmaceuticals have announced that A.P. Pharma has granted an exclusive license to RHEI Pharmaceuticals to develop and sell APF530 in Greater China, which under the agreement includes China, Taiwan, Hong Kong and Macau.
Sanmour Pharma Pvt. Ltd., a Mumbai-based contract pharma research company that provide research-based solutions to the pharmaceuticals majors around the world, have recently entered into technology transfer and partnership agreement with Rx Africa Inc, an Ethiopian-American Partnership Company, to manufacture and market HIV/AIDS related anti- retroviral drugs in Ethiopia to begin with, and later to other parts of Africa and the rest of the world, it was learnt.
As India's clinical trials industry continues to explode, lack of experienced clinical research employees in the region is slowing down progress and leading to fierce poaching between firms.
Xenon Pharmaceuticals Inc. (Xenon) and Takeda Pharmaceutical Company Limited (Takeda) announced that the companies have entered into an exclusive agreement to develop and commercialize oral formulations of Xenon's lead product for pain, XEN401, in Japan and certain Asian countries.
Biogen Idec Inc. and Belgian biopharmaceutical company UCB after Monday's closing bell said they will develop and market CDP323 for the treatment of relapsing-remitting multiple sclerosis.
The national program to fight HIV/AIDS in Liberia says it is concerned about the future of programs distributing antiretroviral (ARV) medicines after a grant from international financing body, the Global Fund to Fight AIDS, Tuberculosis and Malaria, ends in December, according to UN Integrated Regional Information Networks (IRIN).